Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
Journal article published in 2018 by
Catja Freiburghaus,
Venera Kuci Emruli,
Angelica Johansson,
Christian Winther Eskelund,
Kirsten Grønbæk 
,
Roger Olsson,
Fredrik Ek,
Mats Jerkeman,
Sara Ek
,
Roger Olsson,
Fredrik Ek,
Mats Jerkeman,
Sara Ek
This paper is made freely available by the publisher.
Full text: Download
Data provided by 